Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial

医学 偏头痛 安慰剂 双盲 临床试验 传统医学 内科学 药理学 替代医学 病理
作者
Shengyuan Yu,Byung‐Kun Kim,Aihong Guo,Manho Kim,Mingjie Zhang,Zhen Wang,Jianguang Liu,Heui‐Soo Moon,Ge Tan,Qian Yang,Donnie McGrath,Michael Hanna,David Stock,Gao Yanfei,Robert Croop,Zhihong Lu
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:22 (6): 476-484 被引量:24
标识
DOI:10.1016/s1474-4422(23)00126-6
摘要

No acute treatments targeting calcitonin gene-related peptide (CGRP) have been approved for use in China or South Korea. We aimed to compare the efficacy and safety of rimegepant-an orally administered small molecule CGRP antagonist-with placebo in the acute treatment of migraine among adults in these countries.This double-blind, randomised, placebo-controlled, multicentre phase 3 trial was done at 86 outpatient clinics at hospitals and academic medical centres (73 in China and 13 in South Korea). Participants were adults (≥18 years) with at least a 1-year history of migraine who had two to eight moderate or severe attacks per month and fewer than 15 headache days per month within the 3 months before the screening visit. Participants were randomly assigned (1:1) to 75 mg rimegepant or placebo to treat a single migraine attack of moderate or severe pain intensity. Randomisation was stratified by the use of preventive medication and by country. The allocation sequence was generated and implemented by study personnel using an interactive web-response system accessed online from each study centre. All participants, investigators, and the sponsor were masked to treatment assignment. The coprimary endpoints of freedom from pain and freedom from the most bothersome symptom (nausea, phonophobia, or photophobia) 2 h after dosing were assessed in the modified intention-to-treat (mITT) population (randomly assigned participants who took study medication for a migraine attack of moderate or severe pain intensity, and provided at least one efficacy datapoint after treatment) using Cochran-Mantel Haenszel tests. Safety was assessed in all participants who received rimegepant or placebo. The study is registered with ClinicalTrials.gov, number NCT04574362, and is completed.1431 participants were randomly assigned (716 [50%] to rimegepant and 715 [50%] to placebo). 668 (93%) participants in the rimegepant group and 674 (94%) participants in the placebo group received treatment. 1340 participants were included in the mITT analysis (666 [93%] in the rimegepant group and 674 [94%] in the placebo group). 2 h after dosing, rimegepant was superior to placebo for pain freedom (132 [20%] of 666 vs 72 [11%] of 674, risk difference 9·2, 95% CI 5·4-13·0; p<0·0001) and freedom from the most bothersome symptom (336 [50%] of 666 participants vs 241 [36%] of 674 participants, 14·8, 9·6-20·0; p<0·0001). The most common (≥1%) adverse events were protein in urine (8 [1%] of 668 participants in the rimepegant group vs 7 [1%] of 674 participants in the placebo group), nausea (7 [1%] of 668 vs 18 [3%] of 674), and urinary tract infection (5 [1%] of 668 vs 8 [1%] of 674). There were no rimegepant-related serious adverse events.Among adults living in China or South Korea, a single dose of 75 mg rimegepant was effective for the acute treatment of migraine. Safety and tolerability were similar to placebo. Our findings suggest that rimegepant might be a useful new addition to the range of medications for the acute treatment of migraine in China and South Korea, but further studies are needed to support long-term efficacy and safety and to compare rimegepant with other medications for the acute treatment of migraine in this population.BioShin Limited.For the Chinese and Korean translations of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ZSHAN完成签到,获得积分10
刚刚
美满的机器猫完成签到,获得积分10
3秒前
王小磊完成签到,获得积分10
7秒前
谢花花完成签到 ,获得积分10
8秒前
9秒前
瓦罐完成签到 ,获得积分10
9秒前
扁舟灬完成签到,获得积分10
10秒前
Cpp完成签到 ,获得积分10
12秒前
贤惠的老黑完成签到 ,获得积分10
14秒前
ame1120发布了新的文献求助10
14秒前
倦梦还完成签到,获得积分10
16秒前
Sunrise完成签到,获得积分10
17秒前
yyyy发布了新的文献求助10
26秒前
自觉柠檬完成签到 ,获得积分10
30秒前
ergatoid完成签到,获得积分10
30秒前
Hao完成签到,获得积分10
31秒前
月亮煮粥完成签到,获得积分10
31秒前
欣欣完成签到 ,获得积分10
33秒前
现代的紫霜完成签到,获得积分10
34秒前
研学弟完成签到,获得积分10
35秒前
36秒前
jzmulyl完成签到,获得积分10
37秒前
cxdhxu完成签到 ,获得积分10
37秒前
852应助大橙子采纳,获得10
39秒前
务实雁梅完成签到,获得积分10
44秒前
酷波er应助廿伊采纳,获得30
45秒前
47秒前
张宝完成签到,获得积分10
49秒前
薄雪草完成签到,获得积分10
52秒前
大橙子发布了新的文献求助10
52秒前
快乐学习每一天完成签到 ,获得积分10
52秒前
薄荷味完成签到 ,获得积分0
54秒前
科研通AI2S应助笑林采纳,获得10
54秒前
无心的雅旋完成签到,获得积分10
55秒前
量子星尘发布了新的文献求助10
56秒前
Horizon完成签到 ,获得积分10
1分钟前
Oliver完成签到 ,获得积分10
1分钟前
Superman完成签到 ,获得积分10
1分钟前
Tina酱完成签到 ,获得积分10
1分钟前
琪琪完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022